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Abstract The GTPases of the Rho family are molecular
switches that play an important role in a wide range of cellular
processes and are increasingly implicated in tumourigenesis. Un-
like what was found for the Ras oncogenes in tumours, hardly
any activating mutations have been found in the genes encoding
Rho proteins. In the past, we have identi¢ed Tiam1 (T-lympho-
ma invasion and metastasis) as a speci¢c activator for the Rho-
like GTPase Rac. In vivo, Tiam1 de¢ciency protects against
Ras-induced skin carcinogenesis, underscoring the consequences
of deregulated signalling for the onset and progression of tu-
mours. Thus, an important level of regulation of signalling via
the Rho-like GTPases comes from the speci¢c control of their
activators. In this paper, we review what is known on the spe-
ci¢c regulation of Tiam1 signalling towards Rac.
& 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The Rho-like GTPases (which include Rho, Rac and
CDC42) are molecular switches that regulate a wide variety
of cellular processes. They are crucial for cytoskeletal rear-
rangements necessary for cell motility, are involved in cell
cycle progression and regulate gene transcription. It is becom-
ing increasingly clear that they play an important role in tu-
mourigenesis [1]. E.g. both Rho and Rac are involved in the
transformation of cells by the Ras oncogene [2,3]. However,
unlike what was found for Ras, very few (if any) activating
mutations are found in the genes encoding Rho-like proteins.
But given the importance of the GTPases in a spectrum of
biological activities, it comes as no surprise that aberrant reg-
ulation of their activity can lead to several abnormal cellular
phenotypes.
Like the Ras oncogene, these Rho-like GTPases cycle be-
tween an inactive, GDP-bound state and an active, GTP-
bound state. Activation is accomplished by the release of
Rho guanine nucleotide dissociation inhibitor (Rho-GDI)
and exchange of GDP for GTP, catalysed by a class of mol-
ecules known as guanine nucleotide exchange factors (GEF).
When bound to GTP, the GTPases undergo a conformational
change which allows them to bind to their respective down-
stream e¡ector molecules and thereby to transmit the signal.
Proteins that increase the intrinsic rate of GTP hydrolysis of
the GTPase, known as GTPase-activating proteins (GAPs),
inactivate the GTPase and thus shut down the signalling.
Thus, the activity of Rho-like GTPases is determined by the
amount of protein in the GTP-bound form and the time dur-
ing which it is active. This activation state is therefore depen-
dent on the balance of activities of GEFs and GAPs. In turn,
these regulatory molecules themselves (GEFs and GAPs) are
also under tight control.
In the past, we have identi¢ed the Tiam1 protein (for
T-lymphoma invasion and metastasis) as a speci¢c GEF for
the Rho-like GTPase Rac [4]. Although this function of
Tiam1 has been well-established [5], the speci¢c regulation
of its activity is far from being fully understood. In this re-
view, we will focus on the ways in which the activity of Tiam1
is regulated. Apart from increased or decreased expression,
GEFs are basically regulated at four di¡erent levels in the
cell : these include (relief of) intramolecular inhibition,
changes in intracellular localisation, post-translational modi-
¢cations and interaction with other proteins [6] and all of
these seem to apply to Tiam1. Insight into the biochemical
mechanisms governing the activity and localisation of GEFs
such as Tiam1 may lead to a better understanding of the
speci¢c spatio-temporal activation of Rho-like GTPases and
the various ways in which this signalling may be deregulated
in diseases, notably in cancer.
2. Tiam1 regulation; (de-)phosphorylation, phosphoinositol
binding and stability
2.1. Tiam1 structure, auto-inhibition and protein stability
We originally identi¢ed Tiam1 in a retroviral insertional
mutagenesis screen for genes that confer an invasive pheno-
type to otherwise non-invasive murine T-lymphoma cells [4].
The protein possesses the characteristic Dbl homology (DH)^
pleckstrin homology (PH) domain combination, always found
in members of the Dbl-like family of exchange factors (Fig. 1).
The human Tiam1 gene shows a high degree of homology to
its murine counterpart and is widely expressed [7]. The Tiam1
protein is 1591 amino acids long and contains several distinct
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domains (Fig. 1). It is myristoylated at its N-terminus [8],
contains two N-terminal PEST domains, an N-terminal PH
domain (PHn), a coiled-coil region with adjacent sequence
(named CC-ex) [9], a Ras-binding domain (RBD; [10]), a
PSD-95/DlgA/ZO-1 domain and the characteristic catalytic
DH^PH (named PHc) combination. As was shown for other
Dbl-like Rho-GEFs (i.e. Dbl, Vav, Asef, Ect2 and Net1), N-
terminal truncation of Tiam1 (as in C1199-Tiam1) enhances
its in vitro GEF activity and promotes its in vivo association
with the plasma membrane [8]. In the case of Vav [11] and
proto-Dbl [12], intramolecular interactions between an N-ter-
minal K-helix or coiled-coil domain with the DH or its £ank-
ing PH domain, respectively, inhibit the interaction with and
therefore GTP exchange on the Rho-GTPase. However, the
exact mechanism underlying the N-terminal auto-inhibitory
e¡ects of Tiam1 is not yet clear. Like other GEFs, Tiam1
has two consensus PEST domains, located N-terminally of
the PHn domain. PEST domains are believed to function by
targeting proteins to the degradation machinery, hence in-
creasing their turnover (for review, see [13]). Therefore, dele-
tion of these PEST domains probably enhances the stability
and thereby the activity of Tiam1 and other GEFs. Indeed,
truncation of the C-terminal PEST domain of proto-Dbl in-
creases its in vivo GEF activity, membrane localisation and
Fig. 1. Schematic representation of the domain structure of Tiam1. The speci¢c domains of Tiam1 are indicated (from the N-terminus on-
wards): myr: myristoylation site; P: PEST sequence; PHn: N-terminal PH domain; CC: coiled-coil region; Ex: extended structure (without
known fold); RBD: Ras-binding domain; PDZ: PSD-95/DlgA/ZO-1 domain; DH: Dbl homology domain and PHc: C-terminal PH domain.
Proteins reported to interact with certain regions of Tiam1 are indicated above the structure; domains shown to interact with phosphoinositides
are highlighted below the structure. The part of the protein present in the active (C1199) form of Tiam1 is also shown.
Fig. 2. Tiam1-mediated sorting of upstream signals to downstream e¡ects. Schematic drawing showing pathways known to result in Tiam1 ac-
tivity or known to depend on Tiam1 function; the speci¢c interactions of Tiam1 with other proteins determine the outcome of the signalling
(see also text). Known canonical pathways are indicated by di¡erent colours. BetaA-R: L-adrenergic receptor; D2-R: dopamine-2 receptor;
EGF-R: epidermal growth factor receptor; JNK: Jun N-terminal kinase; LPA1 : lysophosphatidic acid receptor-1; PDGF-R: platelet-derived
growth factor receptor; PAK: p21-activated kinase; PHn: N-terminal PH domain; PI3-kinase: phosphatidyl inositol 3-kinase; PIP2: phospha-
tidyl inositol diphosphate; PIP3: phosphatidyl inositol triphosphate; RBD: Ras-binding domain and p70S6K: protein of 70 kDa, S6-kinase.
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oncogenic potential [12]. In contrast, the destruction box in
the PEST domain of Ras-GRF1/2 is only exposed once it
binds to Ras, probably causing Ras-GRF degradation upon
activation of its target GTPase [14]. In case of Tiam1, PEST-
induced N-terminal degradation may account for enhanced
turnover upon activation of Rac. In addition, truncation
might be a potential mechanism to activate the protein in
vivo, since truncated products with increased half-life are
often observed once the full-length Tiam1 protein is expressed
in cells (Mertens et al., unpublished results). Following apo-
ptotic stimuli, caspase-mediated cleavage of Tiam1 has been
shown to be a mechanism of down-regulating Rac activity
and hence inhibiting Rac-induced anti-apoptotic signalling
[15].
2.2. Membrane translocation and activation of Tiam1
Membrane translocation of Tiam1 is crucial for its capacity
to induce Rac-mediated membrane ru¥es and activation of c-
Jun N-terminal kinase [8]. The PHn, rather than the PHc
domain was shown to be critical for membrane localisation
of C1199-Tiam1 [8]. More precisely, the whole PHn-CC-Ex
region was shown to be required, since deletion of the PHn,
CC or Ex domain abolished translocation to the membrane
[9]. Interestingly, we found the isolated PHn-CC-Ex region to
reside primarily at the plasma membrane where it could block
the function of C1199-Tiam1, indicating that Rac binding nor
activation is required for membrane translocation of Tiam1.
The N-terminus of Tiam1 also contains a potential myristoyl-
ation site. However, this lipid anchor probably only stabilises
the protein at the plasma membrane and does not cause its
translocation, since myristoylation could not compensate the
loss of membrane localisation in a Tiam1 mutant that lacks
the PHn domain [8]. Intriguingly, the PHn domain of Tiam1
is a region that has been described to be mutated in cancer
[16]. A single point mutation was reported to cause hyper-
activity of the protein, as assessed by a colony formation
assay. Whether this mutation a¡ects localisation of Tiam1
by interfering with phosphoinositide binding (see below), or
interferes with phosphorylation, is not clear.
The enhanced activity of truncated (C1199) Tiam1 versus
that of the full-length protein is not the mere result of in-
creased protein stability. C1199-Tiam1 is predominantly
present at the plasma membrane [8], probably causing it to
interact more e⁄ciently with prenylated, Rho-GDI-dissoci-
ated Rac [17]. In addition, membrane association brings the
catalytic domain of Tiam1 in close proximity with phospho-
lipids, which might facilitate the exchange reaction (see be-
low). It is currently unclear whether Tiam1 can directly trigger
the association of Rac with the plasma membrane.
Phosphorylation of Tiam1 is another event that may di-
rectly trigger the translocation and/or the activity of the
GEF. Tiam1 was reported to be phosphorylated on threonine
residues by Ca2þ/calmodulin kinase II (CaMK-II) and protein
kinase C (PKC) in vitro and upon treatment of Swiss 3T3
¢broblasts with lysophosphatidic acid (LPA) and PDGF in
vivo [18,19]. More speci¢cally, activation of the LPA1 recep-
tor (formerly named EDG2) by its ligand LPA induces a
robust Rac activation that is dependent on the GEF activity
of Tiam1 [20]. CaMK-II but not PKC was able to stimulate
C1199-Tiam1-induced nucleotide exchange on Rac in vitro,
although to a maximum of only two-fold. However, the ab-
sence of the N-terminal regulatory domain in C1199-Tiam1
makes this result di⁄cult to interpret [18]. Membrane trans-
location and threonine phosphorylation of membrane-bound
Tiam1 upon LPA and PDGF stimulation could only be in-
hibited by CaMK-II inhibition in NIH 3T3 cells [21]. In line
with these observations, PKC inhibition did not a¡ect C1199-
Tiam1-induced T-lymphoma cell invasion, a process totally
dependent on LPA signalling [22], indicating once more that
PKC-mediated Tiam1 phosphorylation probably does not
play a direct role in Tiam1^Rac signalling. On the other
hand, we found that Ca2þ signalling can induce PKC-medi-
ated phosphorylation of Rho-GDI, resulting in release of Rac
and its subsequent activation (Price et al., submitted). How-
ever, this mechanism of Rac activation does not involve
Tiam1. Based on these studies, one can conclude that mem-
brane translocation of Tiam1 is closely associated with its
phosphorylation, but that it is unclear whether phosphoryla-
tion is causal for translocation or full activation of the protein
once it is on the plasma membrane.
Poly-phosphorylated inositol lipids like phosphatidyl inosi-
tol diphosphate (PIP2) and phosphatidyl inositol triphosphate
(PIP3) play an important role in GEF-mediated activation of
Rho-GTPases in processes that require actin cytoskeleton re-
arrangements, such as cell motility and the establishment of
cell polarity [23,24]. However, the exact role of inositol phos-
pholipids in regulation of Tiam1^Rac signalling and GEF
activation in general has been a matter of debate. Together
with Ras-GRF1/2, Tiam1 is the only Dbl family GEF that
contains a second PH domain, in addition to the PH domain
in the catalytic DH^PH unit. In general, the characteristic role
of PH domains (e.g. of those found in pleckstrin, PKB/Akt or
P85 phosphatidyl inositol 3-kinase (PI3-kinase)) lies in protein
localisation through their ability to bind phosphoinositides at
the plasma membrane. In contrast to these PH domains, how-
ever, those in the DH^PH tandem of Dbl-like proteins bind
phospholipids with low a⁄nity and probably require the
synergy with other adaptor modules for e⁄cient membrane
localisation. Indeed, the PHn domain of Tiam1 has higher
a⁄nity for poly-phosphorylated inositides than the PHc do-
main, with a preference of PtdIns(3,4,5)P3 over PtdIns(3,4)P2
and PtdIns(4,5)P2 [19,25]. This is in contrast to the PHc do-
main which has the highest (but relatively low) a⁄nity for
PI(3)P [26]. However, lipid binding to the PHc domain has
been reported to have a direct e¡ect on the catalytic activity
of the associated DH domain.
The DH^PH region of Tiam1 and other GEFs was shown
to mediate nucleotide exchange on Rac in vitro, but the addi-
tion of phosphoinositides (either dissolved or on vesicles) did
not a¡ect the rate of exchange by either the DH^PH region
alone or by C1199-Tiam1 [26]. However, other reports claim
that PI(4)P [27], PI(3,4)P2 and PI(3,4,5)P3 [19] do trigger
GEF activity in vitro. Truncation of the PHc domain in
C1199-Tiam1 totally abolished its capacity to induce mem-
brane ru¥es in cells [27]. In agreement with this observation,
mutations in the PHc domain that abolished PI(3)P binding
but did not a¡ect the in vitro GEF activity of Tiam1 pre-
vented in vivo Rac activation without a¡ecting the membrane
localisation of Tiam1 [28]. Although PI(3)P is mainly found
on endosomal compartments, the authors proposed that high
local concentrations of PIP2 or PIP3 at the plasma membrane
might be able to trigger PHc-driven DH activity.
PI3-kinase activity (which produces PI(3,4)P2, PI(4,5)P2
and PI(3,4,5)P3) has often been implicated in the control of
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Tiam1-driven activation of Rac, probably through its e¡ect
on membrane translocation of Tiam1 [19^21,29]. In MDCK
cells, PI3-kinase inhibition blocked C1199-Tiam1’s capacity to
mediate either cell migration or intercellular adhesion, pro-
cesses that could be rescued by active (V12) Rac [29]. PI3-
kinase activity was also shown to promote C1199-Tiam1-driv-
en Rac activation in Swiss 3T3 cells, a process dependent on
the PHn domain [19]. Intriguingly, PIP3 production did not
cause translocation of the isolated PHn and PHc domains to
the plasma membrane, nor did PI3-kinase inhibition reduce
the ability of C1199-Tiam1 to locate to the plasma membrane
and induce membrane ru¥es. However, truncation of the PHc
domain made C1199-Tiam1-induced membrane ru¥ing de-
pendent on PI3-kinase activity. In addition, C1199-Tiam1-
mediated invasion of T-lymphoma cells is critically dependent
on the activity of PI3-kinase (Roovers et al., unpublished
results).
Rac has been reported to be a critical component during the
¢rst stage of cellular transformation caused by oncogenic Ras
[30] and PI3-kinase activity is found to play a pivotal in this
activation [2]. In addition to a PI3-kinase-dependent, a PI3-
kinase independent Tiam1^Rac signalling pathway has also
been described [10]. This study demonstrates that the signal-
ling of activated Ras to Rac via Tiam1 is at least partially
independent of PI3-kinase activity. It is tempting to speculate
that Ras is able to overcome the dependency of Tiam1 on
PI3-kinase for its signalling to Rac, whereas other signalling
pathways do require PI3-kinase activity for Tiam1-mediated
Rac activation.
Tiam1 might act as a downstream target of cadherin signal-
ling: when the vascular isoform of E-cadherin (VE cadherin)
was re-expressed in VE cadherin null cells, this led to an in-
crease in Tiam1 mRNA and protein levels, an increased mem-
brane localisation of Tiam1 and an increase in Rac activity
[31]. However, it remains elusive whether Tiam1 can directly
interact with the cadherin^catenin complex and whether it is
required for Rac activation downstream of cadherin signal-
ling. Tiam1 was also shown to be a target of heregulin 2
(HER2) signalling in MCF7 breast carcinoma cells [32]. The
HER2 (or cErbB2) oncogene, a member of the epidermal
growth factor receptor family, is frequently over-expressed
in mammary tumours and its signalling is associated with
enhanced metastatic potential. In fact, upon treatment of
MCF7 cells with HER, Tiam1 is phosphorylated and dis-
placed from intercellular adhesions, together with L-catenin
and E-cadherin. In addition, Tiam1 was recruited into mem-
brane ru¥es and this was associated with increased migratory
potential of these cells.
3. Regulation of signalling through protein^protein interactions
Di¡erent members of one GEF family are expressed in
speci¢c cell types and the activity of a given GEF within
one cell is often controlled by a subset of membrane receptors
and intracellular proteins. This hints towards a mechanism of
spatial regulation of GEF activity and restricts the activation
of a given Rho-GTPase to a certain signalling pathway in
time and space. Tiam1 has been implicated to directly bind
to a plethora of di¡erent cytoplasmic and membrane-associ-
ated proteins, which couples Tiam1^Rac activity to speci¢c
signalling pathways. This is schematically depicted in Fig. 2.
An interesting observation in the ¢eld of cancer was that
Ras was shown to mediate Tiam1^Rac signalling (see also
above) through the direct interaction of Ras with the RBD
of Tiam1 [10]. Moreover, the RBD of Tiam1 is required and
su⁄cient for speci¢c binding of Tiam1 to activated Ras. The
fact that Tiam1 knock-out mice were proven to be resistant to
Ras-induced skin tumours underlines the physiological rele-
vance of the connection between Ras and Tiam1 [33].
Tiam1-mediated Rac activation downstream of oncogenic
Ras probably promotes NFUB-mediated cell survival, which
in turn promotes tumour initiation. Loss of intercellular ad-
hesion in the absence of Tiam1^Rac signalling was probably
causal for the enhanced malignant progression of Tiam1 de-
¢cient tumours [33]. In fact, in epithelial MDCK cells, Tiam1^
Rac and Ras signalling seemingly oppose each other, since
V12Ras-induced epithelial^mesenchymal transition is nega-
tively a¡ected by Tiam1^Rac signalling [29,34]. Increasing
Rac activity by introduction of C1199-Tiam1 into MDCK
cells promotes E-cadherin-based cell^cell adhesions and there-
by prevents cell migration [34,35]. In accordance with these
results, down-regulation of endogenous Tiam1 levels in
MDCK cells using short-interference RNA technology causes
a loss of E-cadherin-based intercellular adhesions (van Es et
al., unpublished results). Tiam1-induced restoration of inter-
cellular adhesions in Ras-transformed MDCK cells is inde-
pendent of its capacity to bind Ras, since deletion of the
RBD of Tiam1 does not a¡ect this process (Olivo et al., un-
published results). Thus, Tiam1 either potentiates Ras signal-
ling through direct binding or counteracts its negative e¡ect
on intercellular adhesions via an independent signalling path-
way.
The ¢rst integral membrane protein reported to directly
interact with Tiam1 (and more speci¢cally with the PHn-
CC-Ex domain) is the hyaluronic acid (HA) receptor isoform
CD44v3 [36], which is also concurrently over-expressed in
mammary gland tumours. In parallel, the same domain of
Tiam1 was shown to interact with the cytoskeletal protein
ankyrin [37]. In fact, both CD44v3 and Tiam1 bind to the
ankyrin repeat domains of ankyrin and both CD44v3 and
ankyrin bind to the same domain of Tiam1. Based on these
data one could envisage that Tiam1 binds indirectly to
CD44v3, using ankyrin as the hub. However, the net result
of these interactions for the GEF activity of Tiam1 remains
to be determined. In vitro, ankyrin potentiates C1199-Tiam1-
mediated nucleotide exchange on Rac, but the sequential steps
of Tiam1-induced Rac activation after HA binding to its re-
ceptor are still unclear. Data on recruitment of full-length
Tiam1 and ankyrin to ligand-bound CD44v3 and the resultant
e¡ect on Rac activity are lacking.
The principle that proteins interacting with Tiam1 not only
control its GEF activity, but also determine the downstream
speci¢city of Tiam1-induced Rac signalling is demonstrated in
two recent publications. Yeast two hybrid screens identi¢ed
the sca¡old proteins JIP/islet-brain (JIP/IB2) and spinophilin
(or neurabin II) as proteins binding to the PHn-CC-Ex do-
main of Tiam1 [38,39]. Spinophilin is a ubiquitously expressed
protein that binds protein phosphatase 1 (PP1), F-actin ¢la-
ments, the D2 dopamine receptor and is involved in Rac-
mediated actin reorganisation [40,41]. Notably, PP1 bears
phosphatase activity towards Tiam1 in vitro [18], but it re-
mains unclear whether spinophilin targets PP1 to Tiam1 and
thereby modulates its GEF activity [39]. More importantly,
spinophilin binds to and enhances the activity of p70 S6-ki-
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nase, one of the direct downstream e¡ectors of Rac. Co-ex-
pression of spinophilin and C1199-Tiam1 enhanced S6-kinase
activity in a synergistic manner. In contrast, spinophilin bind-
ing suppressed Tiam1’s ability to activate p21-activated ki-
nase, the downstream target of Rac that mediates actin cyto-
skeletal reorganisation and thus dictates the downstream
e¡ects of Tiam1-mediated Rac activation in a direct manner.
Similarly, the pancreatic L-cell/brain-speci¢c protein JIP2/IB2,
which is a sca¡old for the MLK3-MKK3-p38-mitogen-acti-
vated protein (MAP) kinase complex, was demonstrated to
couple Tiam1-induced Rac signalling to p38 activity [38]. Ec-
topic expression of C1199-Tiam1 not only stimulated the
build up of a complex of JIP2/IB2 with all components of
the p38 signalling cascade, but also enhanced p38 MAP kinase
signalling.
Several recent reports further add candidates to the growing
list of interacting partners of Tiam1. Interestingly, these pro-
teins claimed to interact with Tiam1 are well known players in
the ¢eld of cancer. Firstly, the N-terminus of Tiam1 was
found to interact with the tumour suppressor Nm23H1 [42].
Although the NDP-kinase activity of Nm23H1 can generate
Rac-GTP in vitro, over-expression of Nm23H1 in Rat1 cells
inhibited Tiam1-mediated activation of Rac and Tiam1-in-
duced membrane ru¥ing. However, Nm23H1 also functions
as a GAP for the GTPase Rad, which hints towards the pos-
sibility that the in vivo e¡ects of Nm23H1 expression on
Tiam1^Rac signalling may be due to its function as GAP
towards Rac (which has not been excluded), rather than its
direct inhibitory interaction with Tiam1. In the process of
adherens junction disassembly in MDCK cells, activation of
the GTPase Arf6 was claimed to cause an inhibition of
Tiam1^Rac signalling by means of Nm23H1 [43]. However,
over-expression of Nm23H1 did not alter Rac activity in the
presence of high levels of endogenous Tiam1. Furthermore,
the kinase-dead (H118C) mutant of Nm23H1, that was
claimed to inhibit Tiam1 activity in vivo, did not induce ad-
herens junction disassembly. Therefore, the net e¡ects of
Nm23H1 on Tiam1-induced Rac activity remain rather ob-
scure.
A ¢nal, rather awkward binding partner of Tiam1 is the
oncogene c-Myc [44]. This interaction was reported to be de-
pendent on the Myc-box II domain of c-Myc and to require
the N-terminus (upstream of the PHn domain) of Tiam1. The
authors describe nuclear localisation of Tiam1, although the
protein lacks a putative nuclear localisation signal itself and
clearly does not co-translocate together with c-Myc upon
over-expression. This questions the biological relevance of
the proposed interaction. Moreover, Tiam1 was reported to
inhibit c-Myc-induced transcription and apoptosis in a Rac-
independent manner, although C1199-Tiam1 expression facili-
tated c-Myc-induced apoptosis.
In the case of JIP2/IB2, spinophilin, CD44 and ankyrin, the
PHn-CC-Ex domain of Tiam1 is a minimal prerequisite for
binding to these proteins. Interestingly, the interacting do-
mains of these proteins do not share any sequence or obvious
structural homologies, which raises the question of how the
recognition of these multiple interactors is accomplished. The
coiled-coil region of Tiam1 is a good candidate to be involved
in these multiple interactions, since coiled-coil domains are
£exible and often found to mediate protein^protein interac-
tions [45]. Of all described binding partners of Tiam1, only
spinophilin has a coiled-coil domain that was indeed reported
to mediate the interaction. Moreover, the coiled-coil domain
of Tiam1 may render £exibility on the surrounding PH and
Ex domains, which might represent the actual binding sites for
these proteins. The fact that CD44v isoforms, ankyrins (ANK
1 and 2) and spinophilin are ubiquitously expressed proteins
also raises the problem of steric hindrance: although some of
these proteins might bind in synergy, many of these putative
interactions are probably mutually exclusive. It is therefore
probable that Tiam1 resides in di¡erent micro-domains of
the cell, dependent on its interaction with these proteins. Al-
ternatively, if the amount of Tiam1 is limited within the cell,
regulated (over-)expression of one of its binding partners
might determine the outcome of Tiam1^Rac signalling. Such
a mechanism might account for the seemingly paradoxical
roles Tiam1^Rac signalling plays in tumourigenesis.
4. Concluding remarks
For a large part it is unknown which stimuli, known to
result in activation of Rac, utilise the GEF activity of
Tiam1 to induce this Rac activation. Since the number of
GEFs known to date largely outnumbers the number of
GTPases, one may suspect a great redundancy of GEF func-
tion. This redundancy is partially abrogated by the tissue- and
cell type-speci¢c expression of di¡erent GEFs. In addition,
there is a growing body of evidence that supports the notion
that the speci¢c GEF involved in the activation of a given
GTPase co-determines the downstream e¡ects. Also, as sev-
eral isoforms of Rac have been identi¢ed over the last few
years, it remains to be determined which speci¢c Rac isoform
is involved in a speci¢c signalling pathway that results in
Tiam1 activity.
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